They utilized the covalent inhibitor, MAIM1 (77) (Table 1), which combines with Cys286 of the thalproquinone type, to effectively inhibit Mcl-1 activity (IC50 = 450 nm).228 This compound tightly binds to Mcl-1 and provides potential new pathways and drug precursor compounds for anti-apoptotic tumor therapy. This evidence concerns the gene MCL1 and neoplasm.